Drug company shares are down amid President Donald Trump’s assault on the industry, but some in Congress see value.

Merck & Co., Inc. (NYSE:MRK) is another biopharmaceutical company on the list of the 10 undervalued blue chip stocks analysts ...

The company has raised its payouts for 14 consecutive years, and its nearly 89% growth over the last 10 years provides a ...

Big pharma competes bitterly with the tech giants for the title of most dodgy corporate sector in the world. Given this ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that scientific and commercial team leaders will host a virtual investor event where they will give an overview ...

Merck MRK announced that the phase III HYPERION study evaluating its pulmonary arterial hypertension (“PAH”) drug, Winrevair ...

Merck’s phase 3 HYPERION study of Winrevair meets primary endpoint in recently diagnosed adults with pulmonary arterial hypertension: Rahway, New Jersey Tuesday, June 24, 2025, ...

At this year’s Morningstar Investment Conference in Chicago, Morningstar equity researchers will share their insights on the ...

Historic changes are afoot for pharma as China gains ground on U.S. production. The pharma industry is projected to see ...

In this video, Susana M. Campos, MD, MPH, discusses results from a single-arm phase 2 study of the concurrent treatment of vulvar cancer with chemoradiation and pembrolizumab.Patients who underwent ...

Keytruda (pembrolizumab) is approved for head and neck squamous cell carcinoma as a perioperative treatment regimen.

Stay with Moneycontrol to get real time updates on US MARKET share price, top gainers, top losers and market insights.